What is Plecanatide?
Plecanatide is an oral peptide medicine used for chronic idiopathic constipation and IBS with constipation in adults.
Biological role or research focus
Guanylate cyclase-C signaling in constipation care.
The adult clinical context and pediatric dehydration warning are central to reading the source.
Role reference: MedlinePlus · Plecanatide ↗
Names you may encounter
Trulance
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Uroguanylin-related GC-C agonist
- Main research area
- Adult constipation care
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Source: MedlinePlus · Plecanatide ↗
Quick answers
- Is Plecanatide FDA approved?
- Yes. Trulance (NDA 208745, approved 2017) for chronic idiopathic constipation and IBS with constipation. Source ↗
- Is Plecanatide safe?
- Plecanatide is an oral constipation drug that acts in the gut; diarrhea is the main side effect, and it is barred for young children because it caused fatal dehydration in young mice. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Plecanatide banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Phase 3 constipation study (2017) | Human randomized trial | 1,394 people with chronic idiopathic constipation. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2017
Phase 3 constipation study
A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation.
- Population / model
- 1,394 people with chronic idiopathic constipation.
- Study design
- Twelve-week blinded study of two plecanatide groups versus placebo, using daily bowel diaries.
- Main finding
- Durable complete-spontaneous-bowel-movement response occurred in 21.0% and 19.5% versus 10.2% with placebo. Diarrhea occurred in about 6% versus 1.3%.
- Limits & context
- A higher response rate does not mean everyone responds. This adult constipation trial does not remove pediatric restrictions or apply to bowel obstruction.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
14 registered studies name Plecanatide as an intervention; 1 is recruiting or under way, 0 have not started recruiting yet and 13 completed. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 14 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. ↗
Gastroenterology · 2023 Jun · Practice Guideline, Journal Article
Read available full text ↗
American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. ↗
The American journal of gastroenterology · 2023 Jun 1 · Journal Article, Practice Guideline
Read available full text ↗
Plecanatide. ↗
· 2006 · Review
Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. ↗
The lancet. Gastroenterology & hepatology · 2019 Nov · Journal Article, Research Support, N.I.H., Extramural, Systematic Review, Network Meta-Analysis
Risks & interactions
Plecanatide is an oral constipation drug that acts in the gut; diarrhea is the main side effect, and it is barred for young children because it caused fatal dehydration in young mice.
Risk of serious dehydration in children: not for children under 6, and should be avoided under 18. In young juvenile mice, plecanatide caused deaths from dehydration.
Safety is established by FDA labeling from large placebo-controlled trials in adults with chronic constipation or IBS with constipation. Very little enters the bloodstream. The label lists no drug interactions, and safety under 18 is not established.
No condition tags: its FDA label does not single out these conditions. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
- Children under 6 years old (risk of serious dehydration)
- Children and teens aged 6 to 17: label says avoid
- Known or suspected mechanical bowel obstruction
Serious risks
- Severe diarrhea
- Serious dehydration in children
Common side effects
- diarrhea
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Trulance (plecanatide) prescribing information ↗
Key precautions
Diarrhea, dehydration, bowel-obstruction precautions, and pediatric restrictions are central. Severe diarrhea warrants clinical attention rather than being assumed to be a desirable cleansing effect.
Source: MedlinePlus · Plecanatide ↗
Regulatory status
- U.S. FDA approval
- Approved
Trulance (NDA 208745, approved 2017) for chronic idiopathic constipation and IBS with constipation. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical uses & product context
Its medication reference describes adult constipation conditions. The trial measures a sustained bowel-response definition rather than an unspecified detoxification or repair effect.
Source: MedlinePlus · Plecanatide ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
Mechanism & research rationale
It activates guanylate cyclase-C pathways that support intestinal fluid movement and transit. The desired clinical effect is improved bowel function.
Source: MedlinePlus · Plecanatide ↗
Molecular structure
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- The adult clinical context and pediatric dehydration warning are central to reading the source.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Did every treated participant meet the trial’s responder definition?
No. About one-fifth did, compared with about one-tenth on placebo.
Source: MedlinePlus · Plecanatide ↗
Is it interchangeable with linaclotide?
They act in a related pathway but are different medicines, with their own evidence and instructions.
References & editorial record
- MedlinePlus · Plecanatide ↗
- A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation. ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
